S-nitrosocaptopril nanoparticles as nitric oxide-liberating and transnitrosylating anti-infective technology

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 283-291

  Mordorski, Breanne ^a   Pelgrift, Robert ^b   Adler, Brandon ^a   Krausz, Aimee ^a   da Costa Neto, Alexandre Batista ^b   Liang, Hongying ^b   Gunther, Leslie ^b   Clendaniel, Alicea ^c   Harper, Stacey ^c,d   Friedman, Joel M ^b   Nosanchuk, Joshua D ^b   Nacharaju, Parimala ^b   Friedman, Adam J ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d Oregon State University   (United States)

Author keywords

Antibacterial; E. coli; Nanotechnology; Nitric oxide; Nitrosothiols

Indexed keywords

ANTIMICROBIAL AGENTS; ESCHERICHIA COLI; NANOPARTICLES; NANOTECHNOLOGY;

ANTI-MICROBIAL ACTIVITY; ANTIBACTERIAL; E. COLI; INNATE IMMUNE SYSTEMS; NITROSOTHIOLS; RESISTANCE MECHANISMS; S-NITROSOGLUTATHIONE; ZEBRAFISH EMBRYOS;

NITRIC OXIDE;

CAPTOPRIL; CHITOSAN; GLUTATHIONE; GLUTATHIONE DISULFIDE; NANOPARTICLE; NITRIC OXIDE; S NITROSOCAPTOPRIL; TETRAMETHOXYSILANE; ANTIINFECTIVE AGENT; S-NITROSOCAPTOPRIL;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; EMBRYO; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NITROSYLATION; NONHUMAN; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; WILD TYPE; ZEBRA FISH; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNE SYSTEM; METABOLISM; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCAL INFECTIONS;

DANIO RERIO; ESCHERICHIA; ESCHERICHIA COLI; STAPHYLOCOCCUS;

ANTI-INFECTIVE AGENTS; CAPTOPRIL; ESCHERICHIA COLI; GLUTATHIONE; HUMANS; IMMUNE SYSTEM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NANOPARTICLES; NITRIC OXIDE; STAPHYLOCOCCAL INFECTIONS;

EID: 84922772298     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.017     Document Type: Article

References (29)

1. Pelgrift R.Y., Friedman A.J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 2013, 65(13-14):1803-1815.
2. De Groote M.A., Fang F.C. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis 1995, 21(Suppl. 2):S162-S165.
3. Liew F.Y., Cox F.E. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today 1991, 12(3):A17-A21.
4. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2(10):907-916.
5. Diefenbach A., Schindler H., Rollinghoff M., Yokoyama W.M., Bogdan C. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 1999, 284(5416):951-955.
6. Lee C., Miura K., Liu X., Zweier J.L. Biphasic regulation of leukocyte superoxide generation by nitric oxide and peroxynitrite. J Biol Chem 2000, 275(50):38965-38972.
7. Pawloski J.R., Hess D.T., Stamler J.S. Export by red blood cells of nitric oxide bioactivity. Nature 2001, 409(6820):622-626.
8. Henry P.J., Drummer O.H., Horowitz J.D. S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators. Br J Pharmacol 1989, 98(3):757-766.
9. Kowaluk E.A., Poliszczuk R., Fung H.L. Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin. Eur J Pharmacol 1987, 144(3):379-383.
10. Richardson G., Benjamin N. Potential therapeutic uses for S-nitrosothiols. Clin Sci 2002, 102(1):99-105.
11. Gaston B. Nitric oxide and thiol groups. Biochim Biophys Acta 1999, 1411(2-3):323-333.
12. Friedman A.J., Blecher K., Schairer D., et al. Improved antimicrobial efficacy with nitric oxide releasing nanoparticle generated S-nitrosoglutathione. Nitric Oxide 2011, 25(4):381-386.
13. Chouake J., Schairer D., Kutner A., et al. Nitrosoglutathione generating nitric oxide nanoparticles as an improved strategy for combating Pseudomonas aeruginosa-infected wounds. J Drugs Dermatol 2012, 11(12):1471-1477.
14. Cooke J.P., Andon N., Loscalzo J. S-nitrosocaptopril. II. Effects on vascular reactivity. J Pharmacol Exp Ther 1989, 249(3):730-734.
15. Loscalzo J., Smick D., Andon N., Cooke J. S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. J Pharmacol Exp Ther 1989, 249(3):726-729.
16. Shaffer J.E., Lee F., Thomson S., Han B.J., Cooke J.P., Loscalzo J. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther 1991, 256(2):704-709.
17. Friedman A.J., Han G., Navati M.S., et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008, 19(1):12-20.
18. Truong L., Harper S.L., Tanguay R.L. Evaluation of embryotoxicity using the zebrafish model. Drug Safety Evaluation: Methods and Protocols 2011, Vol. 691:271-279. Humana Press, New York, NY.
19. Ecological Effects Test Guidelines: OPPTS 850.1075 Fish Acute Toxicity Test, Freshwater and Marine 1996, United States Environmental Protection Agency.
20. Nacharaju P., Tuckman-Vernon C., Maier K.E., et al. A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. Nitric Oxide 2012, 27(3):150-160.
21. Uda N.R., Creus M. Selectivity of inhibition of N-succinyl-l, l-diaminopimelic acid desuccinylase in bacteria: the product of dapE-gene is not the target of l-captopril antimicrobial activity. Bioinorg Chem Appl 2011, 2011:306465.
22. Friedman A., Blecher K., Sanchez D., et al. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence 2011, 2(3):217-221.
23. Jarboe L.R., Hyduke D.R., Tran L.M., Chou K.J., Liao J.C. Determination of the Escherichia coli S-nitrosoglutathione response network using integrated biochemical and systems analysis. J Biol Chem 2008, 283(8):5148-5157.
24. Flatley J., Barrett J., Pullan S.T., Hughes M.N., Green J., Poole R.K. Transcriptional responses of Escherichia coli to S-nitrosoglutathione under defined chemostat conditions reveal major changes in methionine biosynthesis. J Biol Chem 2005, 280(11):10065-10072.
25. Pullan S.T., Gidley M.D., Jones R.A., et al. Nitric oxide in chemostat-cultured Escherichia coli is sensed by Fnr and other global regulators: unaltered methionine biosynthesis indicates lack of S nitrosation. J Bacteriol 2007, 189(5):1845-1855.
26. van Sorge N.M., Beasley F.C., Gusarov I., et al. Methicillin-resistant Staphylococcus aureus bacterial nitric-oxide synthase affects antibiotic sensitivity and skin abscess development. J Biol Chem 2013, 288(9):6417-6426.
27. Richardson A.R., Dunman P.M., Fang F.C. The nitrosative stress response of Staphylococcus aureus is required for resistance to innate immunity. Mol Microbiol 2006, 61(4):927-939.
28. Richardson A.R., Libby S.J., Fang F.C. A nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate immunity. Science 2008, 319(5870):1672-1676.
29. Nanomaterial-Biological Interactions Knowledgebase 2010, ONAMI & Oregon State University, [http://nbi.oregonstate.edu/].